×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ZYME – zymeworks inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ZYME
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
02:02 pm
zyme
FDA Approves Ziihera for HER2-Positive Biliary Tract Cancer [Yahoo! Finance]
Low
Report
FDA Approves Ziihera for HER2-Positive Biliary Tract Cancer [Yahoo! Finance]
11/21
06:06 am
zyme
Zymeworks Announces Participation in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Zymeworks Announces Participation in Upcoming Investor Conferences [Yahoo! Finance]
11/21
06:05 am
zyme
Zymeworks Announces Participation in Upcoming Investor Conferences
Medium
Report
Zymeworks Announces Participation in Upcoming Investor Conferences
11/21
06:00 am
zyme
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Medium
Report
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
11/7
07:12 am
zyme
Zymeworks Inc. (NYSE: ZYME) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $25.00 price target on the stock, up previously from $10.00.
Medium
Report
Zymeworks Inc. (NYSE: ZYME) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $25.00 price target on the stock, up previously from $10.00.
11/5
06:00 am
zyme
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-? Expressing Advanced Solid Tumors
Low
Report
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-? Expressing Advanced Solid Tumors
11/4
12:44 pm
zyme
Zymeworks Inc. (NYSE: ZYME) had its price target raised by analysts at Citigroup Inc. from $16.00 to $18.00. They now have a "buy" rating on the stock.
Low
Report
Zymeworks Inc. (NYSE: ZYME) had its price target raised by analysts at Citigroup Inc. from $16.00 to $18.00. They now have a "buy" rating on the stock.
11/1
09:18 am
zyme
Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year [Yahoo! Finance]
Medium
Report
Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/21
04:07 pm
zyme
Form 8-K Zymeworks Inc. For: Nov 21
Neutral
Report
Form 8-K Zymeworks Inc. For: Nov 21
11/14
09:01 pm
zyme
Form SC 13G/A Zymeworks Inc. Filed by: Redmile Group, LLC
Medium
Report
Form SC 13G/A Zymeworks Inc. Filed by: Redmile Group, LLC
11/14
04:27 pm
zyme
Form SC 13G/A Zymeworks Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
Low
Report
Form SC 13G/A Zymeworks Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
11/13
04:31 pm
zyme
Form SC 13G Zymeworks Inc. Filed by: Rubric Capital Management LP
Medium
Report
Form SC 13G Zymeworks Inc. Filed by: Rubric Capital Management LP
10/31
04:16 pm
zyme
Form 10-Q Zymeworks Inc. For: Sep 30
Neutral
Report
Form 10-Q Zymeworks Inc. For: Sep 30
10/31
04:12 pm
zyme
Form 8-K Zymeworks Inc. For: Oct 31
Neutral
Report
Form 8-K Zymeworks Inc. For: Oct 31
10/29
04:11 pm
zyme
Form ARS Zymeworks Inc. For: Dec 31
Low
Report
Form ARS Zymeworks Inc. For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/16
Form 3 Zymeworks Inc. For: Mar 16 Filed by: 667, L.P.
14.0%
3/23 Form DEF 14A Zymeworks Inc. For: May 07 12.5%
1/28 Form 4 Zymeworks Inc. For: Jan 27 Filed by: Cox Troy 12.5%
3/30 Zymeworks Inc (NYSE: ZYME) was downgraded by analysts at TheStreet from a "c" rating to a "d+" rating. 11.1%
11/22 Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress 9.7%
6/19 Zymeworks Announces Pricing of $175.0 Million Public Offering 9.6%
1/13 Form 8-K Zymeworks Inc. For: Jan 12 8.8%
2/8 Zymeworks Inc (NYSE: ZYME) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $51.00 price target on the stock. 7.1%
6/20 Form 424B5 Zymeworks Inc. 7.1%
1/21 Form 424B5 Zymeworks Inc. 6.0%
3/23 Form DEF 14A Zymeworks Inc. For: May 07 12.5%
1/28 Form 4 Zymeworks Inc. For: Jan 27 Filed by: Cox Troy 12.5%
3/30 Zymeworks Inc (NYSE: ZYME) was downgraded by analysts at TheStreet from a "c" rating to a "d+" rating. 11.1%
11/22 Zymeworks Highlights Advancing Clinical Collaboration with BeiGene and Updated ZW25 Phase 1 Data in HER2-Expressing Cancers at ESMO Asia Congress 9.7%
6/19 Zymeworks Announces Pricing of $175.0 Million Public Offering 9.6%
1/13 Form 8-K Zymeworks Inc. For: Jan 12 8.8%
2/8 Zymeworks Inc (NYSE: ZYME) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $51.00 price target on the stock. 7.1%
6/20 Form 424B5 Zymeworks Inc. 7.1%
1/21 Form 424B5 Zymeworks Inc. 6.0%
TOP News Decliners
3/16
Zymeworks Appoints Dr. Kelvin Neu to the Board of Directors
-16.2%
3/11 Form 4 Zymeworks Inc. For: Mar 10 Filed by: Tehrani Ali -10.9%
1/23 Zymeworks prices $279M equity offering [Seeking Alpha] -7.7%
2/24 Zymeworks to Present at Raymond James 41st Annual Institutional Investors Conference -7.1%
1/27 Form 424B8 Zymeworks Inc. -7.0%
3/3 Zymeworks Inc (NYSE: ZYME) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -6.7%
6/18 Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants -6.7%
11/21 Zymeworks Inc (NYSE: ZYME) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. -5.9%
1/10 Zymeworks Inc (NYSE: ZYME) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $61.00 price target on the stock. -5.9%
5/29 Form SC 13G/A Zymeworks Inc. Filed by: CTI Partners, L.P. -5.2%
3/11 Form 4 Zymeworks Inc. For: Mar 10 Filed by: Tehrani Ali -10.9%
1/23 Zymeworks prices $279M equity offering [Seeking Alpha] -7.7%
2/24 Zymeworks to Present at Raymond James 41st Annual Institutional Investors Conference -7.1%
1/27 Form 424B8 Zymeworks Inc. -7.0%
3/3 Zymeworks Inc (NYSE: ZYME) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -6.7%
6/18 Zymeworks Files Preliminary Prospectus Supplements for Offering of Common Shares and Pre-Funded Warrants -6.7%
11/21 Zymeworks Inc (NYSE: ZYME) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. -5.9%
1/10 Zymeworks Inc (NYSE: ZYME) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $61.00 price target on the stock. -5.9%
5/29 Form SC 13G/A Zymeworks Inc. Filed by: CTI Partners, L.P. -5.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: